Noxafil Approved for Treatment of Oropharyngeal Candidiasis

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 11
Volume 15
Issue 11

The FDA has approved Schering-Plough's novel triazole antifungal agent Noxafil (posaconazole) Oral Suspension for the treatment of oropharyngeal candidiasis, including infections refractory to itraconazole and/or fluconazole.

ROCKVILLE, Maryland--TheFDA has approved Schering-Plough'snovel triazole antifungal agent Noxafil(posaconazole) Oral Suspension for thetreatment of oropharyngeal candidiasis,including infections refractory to itraconazoleand/or fluconazole. The drugrecently received FDA approval for theprevention of invasive Aspergillus andCandida infections in patients 13 years ofage and older who are at high risk ofdeveloping these infections due to beingseverely immunocompromised, such ashematopoietic cell transplant recipientswith graft-vs-host disease or those withhematological malignancies with prolongedneutropenia from chemotherapy(see ONI October 2006, page 1).

The FDA approval of Noxafil for treatingoropharyngeal candidiasis is basedprimarily on the results of a randomized,controlled, evaluator-blinded clinicalstudy in HIV-infected patients that comparedNoxafil with fluconazole, as well asa noncomparative study of Noxafil inHIV-infected patients with oropharyngealcandidiasis refractory to treatmentwith fluconazole or itraconazole.

Recent Videos
Artificial intelligence may have the potential to enrich pathology practices to help identify aspects of tumor biology not seen with the human eye.
4 experts are featured in this series.
3 experts in this video
4 experts are featured in this series.
4 experts are featured in this series.
3 experts in this video
4 experts are featured in this series.
Efficacy results from the MASAI trial preceded the creation of the UK-funded EDITH trial, assessing 5 AI platforms in 700,000 women undergoing mammography.
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
Related Content